CAMPCAMP4 Therapeutics Corporation

$125M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$68M-16.6% YoY

Gross Profit

$28M41.0% margin

Operating Income

-$4M-6.5% margin

Net Income

-$9M-13.4% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

-0.6%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$10M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$392M

Total Liabilities

$316M

Stockholders' Equity

$75M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$68M	$82M	-16.6%
Gross Profit	$28M	$35M	-18.9%
Operating Income	-$4M	-$289,000	-1429.1%
Net Income	-$9M	-$9M	-5.2%

Revenue Segments

Product

$39M57%

Application Subscriptions And Other Services

$29M43%

Geographic Segments

UNITED STATES

$47M69%

E M E A

$12M18%

L A S F

$5M7%

Asia Pacific

$3M5%

All Other

$444,0001%

CAMP Q1 2022 Earnings — CAMP4 Therapeutics Corporation Revenue & Financial Results | Market Cap Arena